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Abstract: Aims: Nitric oxide (NO) is increased in the respiratory tract in pulmonary infections. The aim was to determine 
whether nasal wash NO metabolites could serve as biomarkers of viral pathogen and disease severity in children with 
influenza-like illness (ILI) presenting to the emergency department (ED) during the 2009 influenza A H1N1 pandemic. 
Methods: Children ?18 years old presenting to the ED with ILI were eligible. Nasal wash specimens were tested for NO 
metabolites, nitrate and nitrite, by HPLC and for respiratory viruses by real-time PCR. 
Results: Eighty-nine patients with ILI were prospectively enrolled during Oct-Dec, 2009. In the entire cohort, nasal wash 
nitrite was low to undetectable (interquartile range [IQR], 0 - 2 μM), while median nitrate was 3.4 μM (IQR 0-8.6). 
Rhinovirus (23%), respiratory syncytial virus (RSV) (20%), novel H1N1 (19%), and adenovirus (11%) were the most 
common viruses found. Children with RSV subtype B-associated ILI had higher nitrate compared to all other viruses 
combined (P=0.002). 
Conclusion: Concentration of NO-derived nitrate in nasal secretions in children in the ED is suggestive of viral pathogen 
causative for ILI, and thus might be of clinical utility. Predictive potential of this putative biomarker for ILI needs further 
evaluation in sicker patients in a prospective manner. 
Keywords: Acute respiratory infections, emergency department, nitrate, Novel H1N1, pediatrics, RSV. 
1. INTRODUCTION 
 Pandemics like the 2009 novel swine-origin influenza A 
(H1N1) virus (nH1N1) pose significant challenges: increased 
transmission relative to seasonal influenza [1], severe disease 
in patients with medical co-morbidities [1], and difficulty in 
predicting which children with viral respiratory symptoms 
are at risk for influenza complications. In the evaluation of 
acutely ill children in emergency department (ED) settings, 
risk stratification may be achieved by utilizing biomarkers, 
augmenting clinical decision-making, thus improving 
outcomes. 
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 During influenza virus infection, epithelial cells, 
macrophages, lymphocytes and other cells release a complex 
series of cytokines and chemokines in an attempt to 
overcome viral replication and disease progression [2-4]. 
Nitric oxide (NO) [5-8], a key mediator of airway 
inflammation [9], is also released. It is unclear if increased 
NO activity is a marker of clinical disease, of the innate 
antiviral response, or associated significantly with a unique 
respiratory virus infection. In the murine model of 
respiratory syncytial virus (RSV) for instance, NO 
production in the lungs appears to be associated with viral 
clearance and lung disease [5]. Inducible nitric oxide 
synthase (iNOS) activity and production of NO was 
associated with enhanced clearance of RSV, yet they were 
also associated with airway inflammatory changes and 
airway dysfunction [5]. In murine studies of experimental 
influenza A-triggered pneumonia, excessive NO 
biosynthesis, as measured by its metabolites nitrate and 
nitrite, was demonstrated in the lungs [6, 7]. This suggested 
that the metabolites may be markers of influenza-mediated 
disease in the respiratory tract. In humans, NO is produced in 
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the upper and lower respiratory tract. It can be detected in 
exhaled air of healthy individuals and at increased levels in 
subjects with pulmonary disease, including asthma, 
bronchiectasis and upper respiratory infections [10-14]. In 
aqueous solutions, NO is rapidly converted to distinct oxides 
of nitrogen [10, 15], which may thus be potential biomarkers 
of disease severity in acutely ill children presenting with 
influenza-like-illness (ILI). 
 We conducted this as a pilot study to test the hypothesis 
that concentration of NO metabolites, nitrite and nitrate, in 
respiratory secretions would be dependent on type of viral 
pathogen and severity of illness. Our primary objective was 
to describe stable nitrate and nitrite in nasal wash secretions 
as potential indicators of viral pathogen causative of the ILI 
in children who presented to the pediatric ED during the 
2009 nH1N1 pandemic. Our secondary objective was to 
determine if NO metabolites in nasal wash secretions were 
predictive of disease severity. 
2. MATERIAL AND METHODS 
2.1. Study Design/Patient Enrollment 
 We performed a cross-sectional single-center 
convenience study evaluating nasal wash (NW) nitrate and 
nitrite in children 0-18 years of age presenting to the 
emergency department (ED) of Texas Children’s Hospital 
(Houston, TX) with ILI from October 1-December 31, 2009. 
Patients were included if they had an ILI (met the Centers 
for Disease Control and Prevention case definition for ILI 
[16]) or a positive point-of-care test for influenza. The study 
period overlapped part of the 2009 nH1N1 and RSV 
outbreaks in Houston. Institutional review board approval 
was obtained prior to study initiation (IRB#H-25083). After 
informed consent, clinical data were entered into standard 
case reporting forms. These included patient age, gender, 
ethnicity, medical history, vital signs, and physical 
examination findings. A nasal wash sample was also 
collected. 
2.2. Nasal Wash Collection and Processing/Storage 
 During the child’s visit to the ED, a nasal wash (NW) 
sample was collected by a standardized method previously 
described by our team [17]. We instilled 2 mL of normal 
saline into one of the external nares. A flexible rubber tube 
was then utilized to aspirate the material back into a syringe 
containing 2 mL of normal saline. This was repeated in the 
other naris, and the samples pooled. One ml of NW was 
transferred to a cryovial and rapidly frozen to -20°C, and 
later analyzed for NOx (see below). The remaining nasal 
wash was added to transport medium with a virus stabilizer 
(15% glycerol in Iscove’s media), in a 1:1 dilution. This was 
refrigerated at 4°C for no longer than 72 h. It was then 
processed for viral isolation as described below (see also ref. 
[17, 22]). 
2.3. Viral Diagnostics 
 Viral detection was performed by real-time PCR for a 
panel of respiratory viral pathogens that included nH1N1, 
seasonal influenza A (H1N1) virus, parainfluenza virus 1, 
RSV-A and RSV-B, human rhinovirus (HRV), adenovirus, 
enterovirus and human metapneumovirus. 
2.4. Nasal Wash Nitrate and Nitrite Assessment 
 Nasal wash NOx (combined nitrate and nitrite) analysis 
was performed in the laboratory of Dr. Nathan Bryan. After 
thawing an aliquot of nasal secretion, NOx analysis was 
conducted by a dedicated ENO-20 HPLC System (EiCom 
Corporation) [18]. This system is sensitive and selective for 
the measurement of nitrate and nitrite in all biological 
matrices and has the capacity for high throughput (lower 
limit of detection is 0.1 pmol at 100?l of sample injection). 
The ENO-20?s high sensitivity is attained by the combination 
of a diazo coupling technique with the extract to be 
measured and separation of nitrite and then nitrate using a 
reverse-phase column. To separate nitrite and nitrate, the 
nitrate was first reduced to nitrite through a reaction with 
cadmium and reduced copper inside a reduction column. The 
two resolved peaks were then mixed with Griess reagent 
(dinitrogen trioxide, N2O3, generated from acidified nitrite 
that reacts with sulfanilamide) in-line to form the classical 
diazo compound which was then detected spectrophotomet-
rically. Triplicate determinations were performed on each 
specimen and the final values averaged. 
2.5. Detection of IgA and IgG Immunoglobulins in Nasal 
Wash 
 Prior to initiating the study, personnel were trained in a 
standardized nasal wash collection method we previously 
used in a bronchiolitis study conducted in the ED [17, 22]. 
Unlike the previous clinical study, multiple persons were 
involved in the collection of nasal wash specimens in the 
current study. Also consistent with the prior bronchiolitis 
study, the nasal wash specimens were diluted up to eight-
folds to ensure adequate volume to conduct the planned 
assays. We used the detection of IgA and IgG 
immunoglobulins in the nasal wash specimen as markers of a 
“good quality” specimen. Capture ELISA assays specific for 
IgA and IgG immunoglobulins were performed as previously 
described from this laboratory [23]. A 1/32 dilution in 
duplicate of each nasal wash specimen was tested for IgA 
and IgG immunoglobulins. The lower limit of detection for 
the diluted nasal wash specimen was approximately 60 ng/ml 
for total IgA and 114 ng/ml for total IgG. The detection of 
either IgA or IgG immunoglobulin indicated the specimen 
was of “good quality”. In general, all nasal wash specimens 
with detectable IgA also had detectable IgG immunoglobulin 
except for one specimen that only had detectable IgA 
immunoglobulin. 
2.6. Statistical Analysis 
 Stata Version 10 (Stata, Inc., College Station, TX) was 
used for statistical analyses. Patient demographic 
characteristics were described using frequencies for 
categorical variables and measures of central tendency and 
dispersion for continuous variables. Distributions were 
explored for NW nitrite and nitrate concentrations; all were 
found to be non-Gaussian in distribution; as such, non-
parametric tests were used (Kruskal-Wallis test for multiple 
groups and Mann-Whitney U test for two groups) to make 
statistical comparisons across groups. P values less than 0.05 
were considered statistically significant. Comparisons were 
made across groups with nH1N1 infection, non-nH1N1 viral 
infection, and no viral infection detected as well as across 
groups with a single viral infection, co-viral infections, and 
no viral infection detected. We also statistically explored if 
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NW nitrate level was higher in children with more severe 
ILI. When estimates were calculated for all samples 
(overall), a value of zero was assigned to each undetectable 
nitrate value. Therefore, zero values were part of the 
parameter estimation and statistical comparisons for these 
samples. When estimates were calculated for samples with 
detectable nitrate, a missing value was assigned to each 
undetectable nitrate sample. Therefore, undetectable samples 
were excluded from parameter estimation and statistical 
comparisons. 
3. RESULTS 
3.1. Demographics/Clinical Follow-Up 
 A nasal wash specimen was collected on 88 of the 89 
subjects enrolled. Median age was 1.7 years (range 1 mo-
18y); 44% were male, 68% were Hispanic. Sixteen patients 
(18%) were hospitalized. The median hospital length of stay 
was 2 days (range 1 to 6 days). Only 1 patient was admitted 
to the intensive care unit during hospitalization. Six patients 
(7%) required oxygen but none were intubated. Age, gender, 
ethnicity, and clinical outcomes, including hospitalization, 
supplemental oxygenation and intravenous fluid usage, were 
compared between subjects with ILI infected with nH1N1, 
non-nH1N1viruses, or no virus detected: no significant 
differences were found (Table 1). 
3.2. Virologic Results 
 A virologic diagnosis was obtained in 60 (68%) of 88 
patients with ILI presenting to the ED. HRV (n=20; 23%), 
RSV (n=18; 20%), nH1N1 (n=17; 19%), and adenovirus 
(n=10; 11%) were the most commonly detected viruses. Co-
Table 1. Demographic Characteristics, Clinical Outcomes and Nasal Wash Nitrate Between Subjects with ILI Infected with Novel 
(n) H1N1, Non-nH1N1 Viruses or No Virus Detected, at the TCH ED During the 2009 nH1N1 Pandemic 
 
  
Total  
N=88  
(%) 
nH1N1 Virus  
Positive Group  
n=17 (%) 
Non-nH1N1 Virus
¥
  
Positive Group  
n=43(%) 
No Vírus 
 Detected  
Group n=28(%) 
P-Value 
Age in Months: Median (IQR) 20 (6-57) 59 (7-85) 11 (5-22) 33 (11-84) 0.002* 
Gender     0.415** 
Male 39 (44%) 9 (53%) 16 (37%) 14 (50%)  
Female 49 (56%) 8 (47%) 27 (63%) 14 (50%)  
Ethnicity/Race     0.051** 
Hispanic 60 (68%) 15 (88%) 30 (70%) 15 (54%)  
Non-Hispanic 28 (32%) 2 (12%) 13 (30%) 13 (46%)  
Black 2 0 2 0  
White 15 1 6 8  
Asian 11 1 5 5  
Clinical Outcomes      
Hospitalized 16 (18%) 2 (12%) 10 (23%) 4 (14%) 0.472** 
Hours in ED: Median (IQR)
+
 3.6 (2.3-5.1) 3.5 (2.0-5.1) 3.5 (2.6-5.3) 4.1 (1.9-5.1) 0.873* 
Supplemental Oxygen 6 (7%) 0 (0%) 4 (9%) 2 (7%) 0.435** 
Hours of Oxygen: Median (IQR) 34 (12-55) NA 42 (31-79) NA 0.064* 
Intravenous Fluids (IVF) 14 (16%) 1 (6%) 8 (19%) 5 (18%) 0.451** 
Hours of IVF: Median (IQR) 21 (5-40) NA 33 (19-41) 9 (3-18) 0.057* 
Healthcare visit after discharge 18 (21%) 5 (29%) 6 (15%) 7 (26%) 0.377** 
Nasal Wash Nitrate (?M)      
Median (IQR) Nitrate (overall) 3.4 (0.0-8.6) 2.2 (0.0-10.8) 4.7 (0.2-11.5) 1.6 (0.0-4.9) 0.076* 
Nitrate Detectable     0.647** 
Nitrate Undetectable 26 (30%) 6 (35%) 10 (23%) 10 (36%)  
Missing 1 (2%) 0 (0%) 1 (2%) 0 (0%)  
Nitrate Detectable 61 (69%) 11 (65%) 32 (74%) 18 (64%)  
Median (IQR) Nitrate (when Detected) 5.3 (3.0-11.3) 5.3 (2.2-13.5) 7.5 (3.6-14.4) 4.3 (1.7-5.6) 0.061* 
Nasal Wash IgA Detected 61 (69%) 11 (65%) 39 (91%) 11 (39%) <0.0001** 
¥Most common viruses identified were rhinovirus, RSV and adenovirus. 
+For patients discharged home from the ED. 
*Kruskal-Wallis Test; ** Chi-Square Test. 
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infections were observed in 22% of those with any virologic 
diagnosis obtained; 32% had no virus detected. Demographic 
features and clinical outcomes when comparing children 
with ILI due to single viral infections, co-infections or those 
with no virus detected are presented in Table 2: no 
significant differences were found. 
3.3. Nasal Wash Nitrite and Nitrate Results 
 Nasal wash nitrite level was low in the children enrolled 
in our study (range 0.001-2 μM). Nasal wash nitrite 
concentration in children with ILI was not significantly 
different between the children infected with nH1N1, non-
nH1N1 virus and no virus detected (data not shown). 
 Overall, median nitrate concentration was 3.4 μM; 
interquartile range (IQR) 0-8.6. Table 1 compares NW 
nitrate concentration between nH1N1 virus positive, non-
nH1N1 virus positive and no virus detected groups. 
Significant difference in the NW nitrate concentration was 
not observed between the groups. The levels were 
comparable between the groups when only those specimens 
were analyzed in which nitrate was detectable (Table 1). 
 We were interested in conducting exploratory analysis 
with RSV because of the higher NW nitrate level observed 
with single infections. An ad hoc analysis demonstrated that 
RSV-B infection was associated with significantly higher 
nitrate levels, when compared against non-RSV-B infections 
(p =0.002; Fig. 1A) or specifically versus RSV-A infections 
(p=0.009; Fig. 1B). 
 We also compared nitrate levels between single versus 
co-infections and found that they were not significantly 
different from the no virus detected group (Table 2). The 
concentration of NW nitrate was higher in the co-infection 
group, although it was not significantly different even when 
only those specimens were analyzed in which nitrate was 
detectable (Table 2). 
Table 2. Demographics, Clinical Outcomes and Nasal Wash Nitrate Compared Between Subjects with ILI Infected with Single 
Virus, Co-Viruses and those with No Virus Detected, at the TCH ED During the 2009 nH1N1 Pandemic 
 
 Single Virus Infection n=47 (%) Co-Virus Infection n=13 (%) No Virus Detected n=28 (%) 
Age in Months: Median (IQR) 14 (6-47) 12 (4-25) 33 (11-84) 
Gender    
Male 20 (43%) 5 (38%) 14 (50%) 
Female 27 (57%) 8 (62%) 14 (50%) 
Ethnicity/Race    
Hispanic 35 (75%) 10 (77%) 15 (54%) 
Non-Hispanic 12 (25%) 3 (23%) 13 (46%) 
Black 2 0 0 
White 5 2 8 
Asian 5 1 5 
Clinical Outcomes    
Hospitalized 8 (17%) 4 (31%) 4 (14%) 
Hours in ED: Median (IQR)
+
 3.5 (2.3-5.5) 3.3 (2.3-4.0) 4.1 (1.9-5.1) 
Supplemental Oxygen 3 (6%) 1 (8%) 2 (7%) 
Hours of Oxygen: Median (IQR) NA NA NA 
Intravenous Fluids (IVF) 7 (15%) 2 (15%) 5 (18%) 
Hours of IVF: Median (IQR) 33 (18-70) NA 9 (3-18) 
Healthcare visit after discharge 11 (4%) 0 (0%) 7 (26%) 
Nasal Wash Nitrate    
Median (IQR) Nitrate* 3.5 (0.0-11.3) 5.3 (2.9-12.4) 1.6 (0.0-4.9) 
Undetectable 14 (30%) 2 (15%) 10 (36%) 
Missing 1 (2%) 0 (0%) 0 (0%) 
Nitrate Detectable 32 (68%) 11 (85%) 18 (64%) 
Median (IQR) Nitrate** 8.2 (3.0-13.2) 6.8 (3.5-15.9) 4.3 (1.7-5.6) 
Nasal Wash IgA Detected 37 (79%) 13 (100%) 11 (39%) 
+For patients discharged home from the ED. 
*For all samples (p=0.079 by Kruskal-Wallis Test). 
** For samples with detectable nitrate (p=0.070 by Kruskal-Wallis Test). 
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Fig. (1). Nasal wash nitrate in children with and without RSV 
subtype B-mediated influenza-like illness presenting to the 
emergency department during the 2009 influenza pandemic. Data 
include single as well as co-infections. (A) RSV-B positive vs RSV-
B negative; (B) RSV-B positive vs RSV-A positive. The box 
depicts the range of values between the 25
th
 and 75
th
 percentiles 
with a line showing the median; whiskers encompass the adjacent 
values within 1.5 interquartile range of the nearer quartile. 
 We explored if NW nitrate level was higher in children 
with more severe ILI. The median nitrate concentration was 
7.8 μM (IQR 3.1-15.8) for hospitalized children and 4.9 μM 
(IQR 2.9-10.3) for children discharged from the ED; this was 
not significantly different (p=0.533 by Mann-Whitney U 
Test). 
3.4. Specimens with Detectable IgA and IgG 
 We expected to detect a virus in at least 80% of children 
who were enrolled in the study using real time PCR. To 
determine if the nasal wash specimens were of “good 
quality,” we tested all the samples for IgA and IgG 
immunogloublins. Twenty seven (30.7%) of the 88 nasal 
wash specimens we tested did not have detectable IgA or 
IgG immunoglobulins. We then compared the percentage 
with virus detected in the “good quality” versus “poor 
quality” nasal wash specimens: 50 (82%) of 61 good quality 
specimens versus 10 (37%) of 27 poor quality specimens 
were positive for one or more viruses (chi-square; p < 
0.001). 
 Nasal wash samples with detectable immunoglobulins 
were significantly more likely (RR 2.2; 95% CI: 1.34-3.67) 
of having a virus detected compared to nasal wash samples 
with non-detectable IgA or IgG immunoglobulins. Because 
of this significant difference in detecting a virus in “good” 
versus “poor” quality nasal wash specimens, an ad hoc 
analysis was conducted with only specimens considered of 
good quality. 
 In Table 1, the distribution of IgA positive samples by 
ILI groups (nH1N1 virus positive, non-nH1N1 virus 
positive, and no virus detected) is presented with no 
significant difference in distribution. Table 2 describes the 
distribution of IgA positive samples by number of viral 
pathogens detected (single viral infection, co-viral infection, 
and no virus detected groups) and again there was no 
significant difference between groups. 
 When only those subjects with detectable IgA and IgG in 
their nasal wash specimen was analyzed we found no 
significant differences in age, gender, ethnicity or clinical 
outcomes (Table 3). Furthermore, NW nitrate concentration, 
overall as well as when analyzing only specimens in which it 
was detectable, was not significantly different between the 
groups (Table 3). 
4. DISCUSSION 
 The current study is the first of its kind to demonstrate 
potential utility of NW nitrate and nitrite analyses in 
pediatric patients with ILI presenting to the ED. Overall, 
nitrite levels were very low, while nitrate was detectable in 
the majority of patients with ILI. These data are consistent 
with other studies suggesting that nitrate is the predominant 
NO metabolite in the respiratory tract [10, 15], hence that 
may explain why nitrate, and not nitrite, in nasal secretions is 
the more readily detectable of the two. Both nitrite and 
nitrate are stable in aqueous solutions at neutral pH, thus the 
lower concentration of nitrite was not due to lesser stability. 
Furthermore, a study by Grasemann et al. showed that nitrate 
was higher in bronchoalveolar lavage (BAL) fluid from 
children with pneumonia, and that there was a significant 
correlation between plasma and BAL nitrate [10]. 
 Studies have shown a direct correlation and similarity 
between the composition of the upper airway secretions, as 
measured in nasal specimens, and the lower respiratory tract 
fluid, as determined by bronchoalveolar lavage [24]. Given 
the relative ease with which upper respiratory secretions can 
be collected from children, it provided us the rationale for 
studying NOx in nasal lavage. Nasal secretions contain 
multiple proteins, some of which play an important role in 
host defense owing to their antimicrobial potential. We can 
speculate that proteins like lactoferrin or other 
metalloprotiens, found in nasal secretions, may be utilizing 
nitrite as a substrate for NO production and this may be part 
of the antimicrobial activity of nasal secretions. This may 
also explain why nitrite is low in them. Future studies can 
analyze the above proteins to assess whether they are 
increased or to assess their nitrite reductase potential in vitro. 
The utilization of nitrite as a substrate for NO production 
may account for some of the anti-microbial actions of the 
host. 
 The current study was not set up to obtain blood from the 
enrolled patients. One way to demonstrate that a more 
aggressive immune response can be causative for the 
elevated nitrate in NW, could be by assessing correlation 
between the nitrate and peripheral blood white cell counts. 
132    The Open Respiratory Medicine Journal, 2012, Volume 6 Mian et al. 
 Nasal wash nitrate concentration in children with ILI was 
comparable among the children infected with nH1N1 
compared to children infected with other respiratory viruses 
combined or those for whom a virus was not detected. 
Similarly, children with single viral infection versus co-viral 
infection versus those with no detectable viral agent had 
comparable illness outcomes and nitrate levels in their nasal 
wash samples. We were unable to address whether NO or its 
metabolites could be used to gauge severity of disease. This 
was most likely due to an insufficient number of children 
who were hospitalized for comparison. Although not 
statistically significant, nitrate concentration in hospitalized 
children was nearly twice that of non-hospitalized children. 
This might be of clinical relevance; adequately powered 
prospective studies will address this better. Additional 
studies with large numbers of non-hospitalized and 
hospitalized children presenting with an acute respiratory 
illness will be needed to determine if NW nitrate is a reliable 
biomarker for disease severity and can be used to 
complement clinical assessment. 
 The higher concentration of NW nitrate in children with 
RSV versus non-RSV in general, was more marked when the 
analysis was done for RSV subtypes. This is consistent with 
studies that have demonstrated a robust generation of NO as 
part of an innate immune response to RSV [5]. Albeit, our 
patient population was highly selective for ILI based on 
CDC guidelines, the respiratory pathogenesis due to RSV 
may explain the higher concentration of NW nitrate in this 
subgroup. The small numbers of RSV subtypes preclude a 
detailed assessment of the differential levels of nitrate when 
comparing A versus B, we can speculate that the B subtype 
is more pathogenic and thus caused the higher concentration 
of NW nitrate. 
 Exhaled NO has been studied as a putative biomarker for 
respiratory infections caused by influenza, rhinovirus and 
other viral pathogens [19-21], but the data have been 
Table 3. Demographic Characteristics, Clinical Outcomes and Nasal Wash Nitrate Between Subjects with ILI Infected with Novel 
(n) H1N1, Other Viruses, or with No Virus Detected, at the TCH ED During the 2009 nH1N1 Pandemic. Only Specimens 
with Detectable IgA and IgG are Included in the Analysis 
 
 Total N=61 (%) 
nH1N1 Virus 
Positive n=11 (%) 
Non-nH1N1 Virus 
Positive n=39 (%) 
No Virus Detected 
n=11 (%) 
Age in Months: Median (IQR) 12 (6-41) 47 (7-76) 11 (5-20) 60 (9-115) 
Gender     
Male 36 (59%) 6 (54%) 24 (61%) 6 (54%) 
Female 25 (41%) 5 (46%) 15 (39%) 5 (46%) 
Ethnicity/Race     
Hispanic 40 (66%) 10 (91%) 27 (69%) 3 (27%) 
Non-Hispanic 21 (34%) 1 (9%) 12 (31%) 8 (73%) 
Black 2 0 2 0 
White 12 0 6 6 
Asian 7 1 4 2 
Clinical Outcomes     
Hospitalized 10 (16%) 0 (0%) 8 (21%) 2 (18%) 
Hours in ED: Median (IQR)
+
 3.5 (2.3-5.1) 3.5 (2.3-5.1) 3.5 (2.6-5.5) 3.8 (1.6-6.8) 
Supplemental Oxygen 3 (5%) 0 (0%) 2 (5%) 1 (9%) 
Hours of Oxygen: Median (IQR) NA NA NA NA 
Intravenous Fluids (IVF) 8 (13%) 0 (0%) 6 (15%) 2 (18%) 
Hours of IVF: Median (IQR) 26.2 (5.9-38.1) NA 3.5 (2.6-5.5) NA 
Healthcare visit after discharge 10 (17%) 2 (18%) 6 (15%) 2 (18%) 
Nasal Wash Nitrate     
Median (IQR) Nitrate* 4.3 (0.5-10.0) 2.2 (0.0-10.3) 4.7 (0.4-11.8) 4.4 (1.8-4.9) 
Undetectable 13 (21%) 3 (27%) 8 (20%) 2 (18%) 
Missing 1 (2%) 0 (0%) 1 (3%) 0 (0%) 
Nitrate Detectable 47 (77%) 8 (73%) 30 (77%) 9 (82%) 
Median (IQR) Nitrate** 5.3 (3.3-12.1) 4.1 (2.1-13.8) 7.5 (3.5-15.8) 4.7 (3.9-6.8) 
+For patients discharged home from the ED. 
*For all samples (p=0.57 by Kruskal-Wallis Test). 
** For samples with detectable nitrate (p=0.476 by Kruskal-Wallis Test). 
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equivocal. The conflicting data above may simply reflect 
technical issues in measuring exhaled NO. This methodology 
is cumbersome to achieve in the pediatric population, either 
in the in-patient or the ED settings. Thus, the strength of our 
study was that we focused on stable NO metabolites in nasal 
secretions. Additionally, NW specimens are easy to perform 
and readily accessible from children with acute respiratory 
illness such as the population of children we studied who 
presented to the ED with ILI. Early diagnosis of influenza 
facilitates initiation of antiviral therapy that may decrease 
morbidity, mortality, and secondary spread within the 
household. However, currently available rapid diagnostic 
assays for influenza are insensitive and false negative results 
may provide undeserved reassurance to clinicians [25, 26]. 
As such, elevated levels of NO metabolites in respiratory 
samples may provide sensitive, albeit nonspecific, evidence 
of viral etiologies. 
 Our study had several limitations. The pilot cohort was 
relatively small and given the lack of severe ILI observed, 
we were unable to detect statistically significant correlations 
between NW NO metabolites nitrate and nitrite and 
important patient outcomes. An adequately powered 
prospective study might demonstrate statistical significance. 
In the future, we will conduct power calculations to ascertain 
what “n” values are needed to reach statistically significant 
differences. 
 Nitrate was undetectable in several samples. The normal 
saline used for the nasal wash was free of nitrite and nitrate. 
The absence of nitrate may be due to low volumes of nasal 
secretions in those particular patients or the volume of saline 
used to collect may have diluted the sample to below the 
detection limit of the HPLC (1nM). However, since we used 
the same volume of saline for each wash in each patient, 
whatever the reason for the undetectable levels of nitrate is 
reflective of that particular patient. Table 2 shows the 
proportion of samples with detectable nitrate. The median 
and ranges are calculated by utilizing the values from the 
samples with detectable levels. Statistical comparisons 
should not be affected since we applied non-parametric tests. 
 The presence of IgA or IgG in nasal wash was used to 
indicate a “good quality” specimen, based on prior 
experience [23]. In approximately 30% of the children, the 
nasal wash specimen was considered “poor quality” based on 
Ig levels (data not shown). However, when only those 
subjects with detectable IgA and IgG in their nasal wash 
specimen were analyzed we found no significant differences 
in age, gender, ethnicity or clinical outcomes. Furthermore, 
NW nitrate concentration, overall as well as when analyzing 
only specimens in which it was detectable, was not 
significantly different between the groups. Hence, it was 
unlikely to be confounding our results; however, 
highlighting this observation will hopefully provide a tool to 
other investigators to evaluate the quality of the nasal wash 
specimen which is not done in most clinical trials. 
5. CONCLUSIONS 
 Overall, this is an early demonstration for the potential of 
NW nitrate as a biomarker for acute respiratory viral 
infections in children presenting to the ED. An adequately 
powered prospective study in the ED, conducted during the 
respiratory viral seasons (fall, winter and spring), having 
good quality NW specimens, and enrolling larger numbers of 
acutely ill children with a wide range of illness severity will 
be required to fully ascertain if NW levels of nitrate can 
predict important clinical outcomes.  
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